Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

Press Release

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

January 6, 2023 – release at 7:30 am CET
Sophia Antipolis, France        

   Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2022:

  • 288,965 shares
  • € 22,074.60
  • Number of executions on buy side on semester: 274
  • Number of executions on sell side on semester: 195
  • Traded volume on buy side on semester: 155,703 shares for € 262,378.38
  • Traded volume on sell side on semester: 100,347 shares for € 178,155.02

   As a reminder:

  • the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:
  • 233,609 shares
  • € 106,207.47
  • Number of executions on buy side on semester: 526
  • Number of executions on sell side on semester: 571
  • Traded volume on buy side on semester: 336,531 shares for € 706,259.94
  • Traded volume on sell side on semester: 314,889 shares for € 660,405.27
  • the following resources appeared on the liquidity account when the activity started:
  • shares
  • € 500,000.00

   The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd , 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

  Buy Side   Sell Side
  Number of executions Number of shares Traded volume in EUR   Number of executions Number of shares Traded volume in EUR
Total 274 155,703 262,378.38   195 100,347 178,155.02
01/07/2022 9 8,000 13,200.00   5 2,265 3,850.50
04/07/2022   1 1,000 1,720.00
05/07/2022 1 1,000 1,700.00   8 2,999 5,248.25
06/07/2022   2 1,000 1,760.00
07/07/2022   7 3,000 5,400.00
08/07/2022   2 1,000 1,840.00
11/07/2022   4 2,972 5,587.36
12/07/2022 3 1,000 1,860.00  
13/07/2022 3 2,000 3,660.00   1 1,000 1,840.00
18/07/2022   6 2,000 3,740.00
19/07/2022 4 4,000 7,320.00   2 201 373.86
20/07/2022   5 1,799 3,382.12
21/07/2022 6 1,364 2,496.12  
22/07/2022 1 636 1,157.52   1 12 22.32
25/07/2022   1 322 592.48
26/07/2022   1 1 1.84
27/07/2022   1 324 596.16
28/07/2022   1 322 592.48
29/07/2022   1 31 57.04
05/08/2022 1 513 933.66   2 41 76.26
08/08/2022   8 3,947 7,459.83
09/08/2022   2 1,100 2,134.00
10/08/2022   8 2,900 5,684.00
12/08/2022   1 292 584.00
15/08/2022   1 708 1,416.00
16/08/2022   5 4,000 8,200.00
17/08/2022 4 2,000 4,060.00  
18/08/2022 4 3,000 6,000.00   1 2,000 4,100.00
19/08/2022 1 84 168.00  
22/08/2022 5 2,946 5,921.46  
23/08/2022 2 970 1,940.00  
24/08/2022   1 2,000 4,000.00
25/08/2022 2 3,500 6,895.00   1 209 418.00
26/08/2022 6 2,500 4,950.00   1 1,291 2,582.00
29/08/2022 3 4,000 7,720.00  
30/08/2022   2 1,000 1,940.00
01/09/2022 6 3,001 5,641.88   1 1 1.93
05/09/2022   1 1,000 1,880.00
  Achats   Ventes
  Nombre de transactions Nombre de titres Capitaux en EUR   Nombre de transactions Nombre de titres Capitaux en EUR
Total 274 155,703 262,378.38   195 100,347 178,155.02
06/09/2022 2 1,177 2,189.22  
07/09/2022 1 823 1,514.32   5 2,000 3,800.00
08/09/2022   2 1,000 1,940.00
09/09/2022   3 2,000 3,980.00
12/09/2022 1 1,000 1,960.00  
14/09/2022 10 4,000 7,840.00  
15/09/2022 3 1,000 1,940.00  
16/09/2022 5 4,000 7,640.00  
19/09/2022 2 1,000 1,880.00   2 4,000 7,760.00
20/09/2022 1 1,000 1,940.00  
21/09/2022 3 3,000 5,730.00   1 1 1.96
22/09/2022 2 1,000 1,880.00  
23/09/2022 8 3,487 6,381.21  
26/09/2022 10 4,000 7,000.00  
27/09/2022 1 1,000 1,700.00   2 1,000 1,760.00
28/09/2022 2 1,102 1,895.44  
29/09/2022 1 898 1,526.60  
30/09/2022   4 1,000 1,720.00
03/10/2022 1 1,000 1,680.00   1 842 1,465.08
04/10/2022   4 3,158 5,621.24
06/10/2022 1 1 1.78   3 1,001 1,821.82
07/10/2022 2 255 459.00  
11/10/2022 2 578 1,040.40  
12/10/2022   2 1,000 1,840.00
13/10/2022 1 1,000 1,830.00   2 1,020 1,897.20
14/10/2022 1 500 925.00   1 1,000 1,880.00
17/10/2022 1 1,000 1,870.00   2 2,000 3,820.00
18/10/2022   7 2,045 3,987.75
19/10/2022   10 5,954 11,788.92
21/10/2022 3 1,200 2,412.00  
24/10/2022   7 4,000 8,160.00
26/10/2022 2 1,014 2,068.56  
27/10/2022 8 3,986 7,932.14  
28/10/2022 2 354 693.84   2 1,000 2,000.00
31/10/2022 30 15,813 29,254.05   5 3,000 6,090.00
01/11/2022 5 3,000 5,220.00  
02/11/2022   4 3,000 5,400.00
08/11/2022 1 1,000 1,720.00  
09/11/2022   1 1 1.74
  Achats   Ventes
  Nombre de transactions Nombre de titres Capitaux en EUR   Nombre de transactions Nombre de titres Capitaux en EUR
Total 274 155,703 262,378.38   195 100,347 178,155.02
10/11/2022 2 1,000 1,700.00  
15/11/2022   4 999 1,738.26
17/11/2022 3 1,000 1,720.00  
18/11/2022 2 657 1,116.90  
21/11/2022 1 843 1,433.10   1 24 41.52
22/11/2022 24 14,000 22,260.00  
23/11/2022 3 3,000 4,440.00  
24/11/2022 2 1,000 1,440.00  
25/11/2022 1 1,000 1,420.00  
28/11/2022 3 2,000 2,780.00  
29/11/2022 6 3,000 3,990.00  
30/11/2022 2 2,000 2,540.00   1 1,000 1,320.00
01/12/2022 2 1,500 1,890.00  
02/12/2022 1 1,000 1,280.00   2 1,000 1,300.00
05/12/2022 1 1,000 1,300.00   5 4,000 5,480.00
06/12/2022 4 4,000 5,160.00  
07/12/2022 2 2,000 2,500.00  
08/12/2022 2 1,000 1,240.00  
09/12/2022 1 1,000 1,220.00   2 1,000 1,260.00
12/12/2022 1 1,000 1,200.00  
13/12/2022 2 1,001 1,181.18   4 2,000 2,420.00
14/12/2022 3 1,972 2,307.24   1 100 119.00
15/12/2022 4 1,028 1,202.76   2 200 238.00
16/12/2022 1 1,000 1,160.00  
19/12/2022 20 3,000 3,450.00  
20/12/2022 6 5,000 5,600.00   3 2,000 2,240.00
21/12/2022 2 1,000 1,100.00  
22/12/2022   2 2,000 2,240.00
23/12/2022   8 3,000 3,360.00
27/12/2022   6 2,265 2,582.10

 

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also conducting research on NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in conditions. NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals for topical ocular application for dry eye disease, is being developed by Ocumension Therapeutics in China under an exclusive license agreement and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC (a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment C: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co         Eric Yoo        Paris, France
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Arsene Guekam        Paris, France

 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
[email protected]

Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
[email protected]

Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2021’ filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022, in its first amendment filed with the AMF on May 19, 2022, in the 2nd chapter of its second amendment filed with the AMF on November 22, 2022 and in the 2nd chapter of the Securities note filed with the AMF on November 22, 2022 which are available on Nicox’s website (www.nicox.com).

Nicox SA
Drakkar 2 – Bât D
2405 route des Dolines
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

 

Attachment

error: Content is protected !!